Archimedes Pharma UK 95 percent of Reading and development facilities in Nottingham. Other European commercial operations in Ireland, France and Germany established. The company was founded in December 2004 and is owned by Warburg Pincus, a leading private equity investor support with extensive experience in health care. In 2007, Archimedes had sales of U.S. $ 40 million.

– to be taken if the problem of bullying and harassment at work is effectively done so, support must be made available to all parties. This includes confidential, non-judgmental support for the victims and also corrective measures assistance for those who harassment bullying. Moreover, a third party, that the bullying and harassment feel empowered challenge the situation or report a suitable manager or colleagues. A copy the BMA report: Bullying and harassment of doctors at work, is available at: bma.nsf/Content/bullying2006.On XMT-1001XMT-1001 is a conjugate of Fleximer and camptothecin , a broad range cytotoxic which topoisomerases I topoisomerase I, of DNA damage on cancerous cells. In former Phase 2 studies shown the free drug CPT detection of anti – tumor activity of but also revealed security concerns, including serious bladder toxicity. Preclinical trials of XMT-1001 in oncology models of considerable improvement over significant improvement over to the clinically active CPT and irinotecan, occupied by broad-spectrum activity with superior efficiency and assurance.